The time it takes to correctly diagnose endometriosis could be slashed from seven years to just a few weeks with a new, non-invasive test from Nedlands-based Proteomics International.
Nedlands-based health tech innovator Proteomics International Laboratories has appointed Eurobio Scientific to distribute its PromarkerD test in France.
Our board moves wrap includes John Jones, Max Johnston, Bruce McHarrie, Krista Bates, Jean-Sebastien Boutet, Phillip Gallagher, John Welborn, Warwick Davies, Richard Nicholls-Maltman, James Eggins, Peter Meagher, Simon Jackson, Robyn Elliott, and Neville Gardiner.
A device to predict kidney disease and a diagnostic imaging tool for cancer surgery are among the innovations awarded a share of $450,000 for commercialisation.
Our board moves wrap includes Deepankar Panigrahi, Alexander Cook, Bahay Ozcakmak, Penelope Creswell, Patrick Power, Terry Sweet, Michael Malone, and Richard Dammery.
Perth-based Proteomics International has partnered with the University of Melbourne and the Royal Women's Hospital to develop a non-invasive blood test for endometriosis.
Our weekly appointments wrap includes Larissa Strk, Peter Sarandopoulos, Simon Ward, Jack Eaton, Colin Cameron, Julie Harris, Jean-Michel Bour, Vik Malik and Jacqueline Gray.
ASX-listed medical technology company, Proteomics International Laboratories' coffers have been further boosted by a $1.1 million research and development tax rebate following a recent successful capital raise of $6 million. The Perth-based company, known for its predictive diagnostic tests, now has approximately $8.5 million in cash reserves including the funds from the share placement and the rebate of $1.13 million from the Australian Taxation Office.
ASX-listed Proteomics International Laboratories has locked away $6m in cash via a heavily oversubscribed placement to UK and local institutions and other sophisticated investors to progress the marketing and development of its ‘PromarkerD' predictive kidney disease test. Euroz-Hartleys Securities Ltd acted as sole lead manager for the placement to new and existing investors and Candour Advisory acted as Corporate Adviser.
ASX-listed medical technology company, Proteomics International Laboratories, has entered into an agreement with Medical Horizons that will see the Italy-based group distribute the easy-to-use immunoassay version of Proteomics' PromarkerD predictive test for diabetic kidney disease in Italy.
ASX-listed Proteomics International has published the findings of a major international, multi-centre clinical study involving more than 3,500 patients which provides the first-ever external support for the efficacy of its PromarkerD diagnostic test. Extraordinarily, patients identified by PromarkerD were 13.5 times more likely to develop Chronic Kidney Disease during a 4-year period.
Novel clinical diagnostics developer, Proteomics International has teamed up with the QMIR Berghofer Medical Research Institute in Queensland to improve and simplify the detection of oesophageal adenocarcinoma, the most common form of oesophageal cancer. Proteomics will use its trademarked Promarker platform with QIMR Berghofer's biomarkers to develop a simple blood test for the cancer, whose incidence is on the rise.
ASX-listed Proteomics International has locked up patent protection throughout much of Asia, Europe and the Americas for its predictive diabetic kidney disease test known as “PromarkerD”. Proteomics said granted patent and trademark protection now covers areas where 59 per cent of the 463 million adults living with diabetes reside after it recently secured patents for Brazil and Canada.
A major clinical study involving 3,000 patients has validated ASX-listed Proteomics' “PromarkerD” predictive test for diabetic kidney disease with the study confirming that PromarkerD has a high probability of predicting a clinical decline in kidney function up to four years in advance of it actually happening. With the major milestone achieved, Proteomics is now looking to commercialise the technology in the USA.
ASX-listed Proteomics International has received a $200,000 boost in funding courtesy of the WA Health Department and the WA Health Translation Network to develop a rapid test for COVID-19 and undertake some ground breaking research into why it attacks some worse than others. Proteomics will make use of its state-of-the-art facilities at the QE11 Medical centre.
West Perth-based Talga Resources is seeking to raise $6.25 million through a share placement and purchase plan, primarily to fund the development of its graphite project in Sweden.
It has taken over 15 years, but Perth-based medical technology company Proteomics International is now launching a commercial product targeted at the US.
Shares in Proteomics International Laboratories have jumped more than 8 per cent in early trading, after the Nedlands-based firm announced a collaboration agreement with a US pharmaceutical company.
Dreamscape Networks is pleased to announce that it has entered into a Binding Heads of Agreement to acquire 100% of Hong Kong based hosting and domain business PacHosting from privately held Pacifi
Westgold Resources Limited is pleased to advise that completion of the sale of the South Kalgoorlie Operations (SKO) to Northern Star Resources Limited as announced on 8 March 2018 occurred on 29 M
Emerging Western Australian nickel company St George Mining is pleased to announce it has successfully raised $4.0 million from institutional and sophisticated investors via a placement at an issue
Two local tech companies have raised more than $5 million, with medical firm Proteomics International Laboratories securing $3.4 million via the exercise of options.
Shares in Nedlands-based Proteomics International Laboratories skyrocketed on news it had produced and validated a predictive test for the diagnosis of diabetic kidney disease.
Nedlands-based Proteomics International Laboratories has made a solid debut on the ASX today, closing 2.5 cents above its issue price at 22.5 cents per share, with about 1.13 million shares changing hands.
Nedlands company Proteomics International Laboratories is hoping for increased support for its initial public offering after finalising an agreement with a Chinese drug development business.
A surge in the number of backdoor listings was one of the few positives on the stock market in 2014, and two new deals for technology companies show there is more to come.
